4//SEC Filing
Uden Stephen 4
Accession 0000899243-22-002043
CIK 0001739410other
Filed
Jan 13, 7:00 PM ET
Accepted
Jan 14, 8:11 PM ET
Size
22.5 KB
Accession
0000899243-22-002043
Insider Transaction Report
Form 4
Rallybio CorpRLYB
Uden Stephen
DirectorChief Executive Officer
Transactions
- Other
Common Stock
2021-07-28+709,127→ 709,127 total - Purchase
Common Stock
2022-01-13$9.06/sh+4,193$37,989→ 718,320 total - Purchase
Common Stock
2022-01-13$9.62/sh+807$7,763→ 719,127 total - Other
Series B Preferred Units
2021-07-28−107,891→ 0 total→ Common Stock (16,944 underlying) - Purchase
Common Stock
2022-01-12$10.55/sh+5,000$52,750→ 714,127 total - Other
Series A-1 Preferred Units
2021-07-28−150,000→ 0 total→ Common Stock (23,557 underlying) - Other
Common Units
2021-07-28−4,820,000→ 0 total→ Common Stock (652,922 underlying) - Other
Series A-2 Preferred Units
2021-07-28−100,000→ 0 total→ Common Stock (15,704 underlying) - Award
Option (Right to Buy)
2021-07-28+160,000→ 160,000 totalExercise: $13.00Exp: 2031-07-28→ Common Stock (160,000 underlying)
Footnotes (5)
- [F1]The Common Units, Series A-1 Preferred Units, Series A-2 Preferred Units and Series B Preferred Units (collectively with the Series A-1 Preferred Units and Series A-2 Preferred Units, the "Preferred Units") reported herein were units of Rallybio Holdings, LLC. The shares of common stock of the Issuer were received on July 28, 2021 pursuant to the Plan of Liquidation and Dissolution, dated July 28, 2021, among Rallybio Holdings, LLC and its members (the "Plan of Liquidation"). Pursuant to the Plan of Liquidation, the holders of Common Units, on an aggregate basis, received approximately 7.38 shares of common stock of the Issuer for each Common Unit and approximately 6.37 shares of common stock of the Issuer for each Preferred Unit. Rallybio Holdings, LLC was subsequently dissolved. The Common Units and Preferred Units had no expiration date prior to the liquidation.
- [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.01 to $11.00, inclusive. The reporting person undertakes to provide to Rallybio Corporation, any security holder of Rallybio Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.29 to $9.28, inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.29 to $10.28, inclusive.
- [F5]The option vests as to 25% of the underlying shares of Common Stock on July 28, 2022 and as to the remaining 75% of the underlying shares of Common Stock in 36 equal monthly installments thereafter.
Documents
Issuer
Rallybio Corp
CIK 0001739410
Entity typeother
Related Parties
1- filerCIK 0001332141
Filing Metadata
- Form type
- 4
- Filed
- Jan 13, 7:00 PM ET
- Accepted
- Jan 14, 8:11 PM ET
- Size
- 22.5 KB